MYCN and survivin cooperatively contribute to malignant transformation of fibroblasts

Carcinogenesis

Volumn 35, Issue 2, 2014, Pages 479-488

  Hipp, Nora I ^a,b   Christner, Lisa ^a   Wirth, Thomas ^b   Mueller Klieser, Wolfgang ^c   Walenta, Stefan ^c   Schröck, Evelin ^d   Debatin, Klaus Michael ^a   Beltinger, Christian ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; SURVIVIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; FIBROBLAST; IN VITRO STUDY; MALIGNANT TRANSFORMATION; MYCN GENE; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL HYPOXIA; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; FIBROBLASTS; GLUCOSE; GLYCOLYSIS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; INHIBITOR OF APOPTOSIS PROTEINS; LACTIC ACID; MICE; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RATS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84893367336     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt341     Document Type: Article

References (55)

1. Wistuba,I.I. et al. (2001) Molecular genetics of small cell lung carcinoma. Semin Oncol., 28(2 Suppl 4), 3-13.
2. Kim,Y.H. et al. (2006) Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene, 25, 130-138.
3. Brodeur,G.M. et al. (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science, 224, 1121-1124.
4. Look,A.T. et al. (1991) Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J. Clin. Oncol., 9, 581-591.
5. Pfister,S. et al. (2009) Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J. Clin. Oncol., 27, 1627-1636.
6. Slack,A. et al. (2005) The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc. Natl Acad. Sci. USA, 102, 731-736.
7. Janardhanan,R. et al. (2009) N-Myc down regulation induced differentiation, early cell cycle exit, and apoptosis in human malignant neuroblastoma cells having wild type or mutant p53. Biochem. Pharmacol., 78, 1105-1114.
8. Swartling,F.J. et al. (2010) Pleiotropic role for MYCN in medulloblastoma. Genes Dev., 24, 1059-1072.
9. Swartling,F.J. et al. (2012) Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell, 21, 601-613.
10. Williamson,D. et al. (2005) Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J. Clin. Oncol., 23, 880-888.
11. Mercado,G.E. et al. (2008) Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes. Chromosomes Cancer, 47, 510-520.
12. Naini,S. et al. (2008) Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res., 68, 9583-9588.
13. Somers,G.R. et al. (2007) Expression of MYCN in pediatric synovial sarcoma. Mod. Pathol., 20, 734-741.
14. Hogarty,M.D. (2003) The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. Cancer Lett., 197, 173-179.
15. Ushmorov,A. et al. (2008) N-myc augments death and attenuates protective effects of Bcl-2 in trophically stressed neuroblastoma cells. Oncogene, 27, 3424-3434.
16. Altieri,D.C. (2003) Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer, 3, 46-54.
17. Mita,A.C. et al. (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res., 14, 5000-5005.
18. Bown,N. et al. (1999) Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med., 340, 1954-1961.
19. Miller,M.A. et al. (2006) Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: a report from the children's oncology group. J. Pediatr. Hematol. Oncol., 28, 412-417.
20. Shankar,S.L. et al. (2001) Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J. Neurochem., 79, 426-436.
21. Lamers,F. et al. (2011) Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocr. Relat. Cancer, 18, 657-668.
22. Pizem,J. et al. (2005) Survivin is a negative prognostic marker in medulloblastoma. Neuropathol. Appl. Neurobiol., 31, 422-428.
23. Haberler,C. et al. (2006) Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome. Eur. J. Cancer, 42, 2996-3003.
24. Caldas,H. et al. (2006) Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo. J. Med. Genet., 43, 119-128.
25. Taubert,H. et al. (2010) Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients. BMC Cancer, 10, 65.
26. Warburg,O. et al. (1927) The metabolism of tumors in the body. J. Gen. Physiol., 8, 519-530.
27. Hanahan,D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
28. Ferreira,L.M. et al. (2012) Metabolic reprogramming of the tumor. Oncogene, 31, 3999-4011.
29. Qing,G. et al. (2010) Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha. Cancer Res., 70, 10351-10361.
30. Hagenbuchner,J. et al. (2013) BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery. Oncogene, 32, 4748-4757.
31. Weidner,N. (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res. Treat., 36, 169-180.
32. Walenta,S. et al. (2000) High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res., 60, 916-921.
33. Small,M.B. et al. (1987) Neoplastic transformation by the human gene N-myc. Mol. Cell. Biol., 7, 1638-1645.
34. Warburg,O. (1928) The chemical constitution of respiration ferment. Science, 68, 437-443.
35. Gatenby,R.A. et al. (2004) Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer, 4, 891-899.
36. Fantin,V.R. et al. (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 9, 425-434.
37. Allan,L.A. et al. (2000) The p21(WAF1/CIP1) promoter is methylated in Rat-1 cells: stable restoration of p53-dependent p21(WAF1/CIP1) expression after transfection of a genomic clone containing the p21(WAF1/CIP1) gene. Mol. Cell. Biol., 20, 1291-1298.
38. Taylor,B.S. et al. (2011) Advances in sarcoma genomics and new therapeutic targets. Nat. Rev. Cancer, 11, 541-557.
39. Piccinin,S. et al. (2012) A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 degradation. Cancer Cell, 22, 404-415.
40. Merlino,G. et al. (1999) Rhabdomyosarcoma-working out the pathways. Oncogene, 18, 5340-5348.
41. Takahashi,Y. et al. (2004) Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod. Pathol., 17, 660-669.
42. Carr,J. et al. (2006) Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res., 66, 2138-2145.
43. Carr-Wilkinson,J. et al. (2010) High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clin. Cancer Res., 16, 1108-1118.
44. Gross,N. et al. (1994) Altered growth and phenotype in clonal mycN transfectants of the SK-N-SH neuroblastoma cell line. Int. J. Cancer, 59, 141-148.
45. Lutz,W. et al. (1996) Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene, 13, 803-812.
46. Lens,S.M. et al. (2006) The case for Survivin as mitotic regulator. Curr. Opin. Cell Biol., 18, 616-622.
47. Altieri,D.C. (2006) The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr. Opin. Cell Biol., 18, 609-615.
48. Lens,S.M. et al. (2003) Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J., 22, 2934-2947.
49. Mehrotra,S. et al. (2010) IAP regulation of metastasis. Cancer Cell, 17, 53-64.
50. McKenzie,J.A. et al. (2010) Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer Res., 70, 7927-7937.
51. Mosier,D.E. et al. (1988) Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature, 335, 256-259.
52. Lania,L. et al. (1980) The polyoma virus 100K large T-antigen is not required for the maintenance of transformation. Virology, 101, 217-232.
53. Shankaran,V. et al. (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 410, 1107-1111.
54. Berry,T. et al. (2012) The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell, 22, 117-130.
55. Otto,T. et al. (2009) Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell, 15, 67-78.